CD274 and neoplasm: For monoclonal antibodies used to block checkpoint molecules, such as PD-1 and PD-L1, to activate immune cells to kill tumor cells more effectively, it may be worth adding designed features such as metal ion binding sites to add to their capabilities or removing free cysteines to improve their stability (284–286).